Immunomodulation in the treatment and/or prevention of bronchial asthma

Robert G. Townley, Russell J. Hopp, Devendra K. Agrawal, Thomas B. Casale, Michael T. Hopfenspirger

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The immunologic hallmark of atopic allergy and asthma is an increased production of IgE and T helper (h) type 2 cell cytokines (interleukin (IL)-4, IL-5, IL-9 and IL-13) by Th cells reacting to common environmental allergens. All of us inhale allergens and healthy non-atopics produce allergen-specific IgG1, IgG4 and the Th1 cytokine interferon-α, as well as IL-12 from macrophages. We now have many modalities of immunomodulation to decrease the effect of IL-4 or IL-5 or production and level of IgE or agents to shift the immune response from a Th2 to a Th1 response, thereby decreasing the allergic inflammatory response in the airways. In the present review we focus on conventional immunotherapy, mycobacterial vaccines, DNA vaccines using cytosine guanosine, inhibitors of IL-4 and IL-5 and anti-IgE: Omalizumab.

Original languageEnglish
Pages (from-to)63-73
Number of pages11
JournalAllergology International
Volume51
Issue number2
DOIs
Publication statusPublished - 2002

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Townley, R. G., Hopp, R. J., Agrawal, D. K., Casale, T. B., & Hopfenspirger, M. T. (2002). Immunomodulation in the treatment and/or prevention of bronchial asthma. Allergology International, 51(2), 63-73. https://doi.org/10.1046/j.1440-1592.2002.00258.x